ArticleDermatology (Basel, Switzerland)2023
Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review.
Article in Dermatology (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 75 citations in OpenAlex.
- Immune shifts in inflammatory skin diseases.JID innovations : skin science from molecules to population health · 2026Review
- A case of dupilumab-induced psoriatic alopecia.Skin health and disease · 2026Article
- Phenotype Switching in Pediatric Inflammatory Skin Diseases During Biologic Therapy: A Literature Review Focused on Atopic Dermatitis and Psoriasis.International journal of molecular sciences · 2026Review
- Sustained Platelet Improvement Temporally Associated with Dupilumab in Chronic Immune Thrombocytopenia: A Case Study.Journal of clinical medicine · 2026Article
- Immunopathogenesis of itch: an integrative framework for chronic pruritus.JID innovations : skin science from molecules to population health · 2026Review
- Type-2-Inflammatory-Diseases Share Comorbidities, Molecular Signatures, IL4/IL13 Genetics, and Response to IL4/IL13 Blockade.Allergy · 2026Article
- Incidence of autoimmune diseases in children with atopy treated with dupilumab.The Journal of allergy and clinical immunology · 2026Article
- Article
- Ostraceous psoriasis in end-stage renal disease: A delayed phenotype switch from dupilumab treated with guselkumab.JAAD case reports · 2026Article
- Severe psoriasis relapse following tralokinumab therapy for atopic dermatitis.JAAD case reports · 2026Article
- Article
- Paradoxical pustular psoriasis following dupilumab therapy for bullous pemphigoid: A case report.JAAD case reports · 2026Article
- Efficacy and Safety of Dupilumab in Immune Checkpoint Inhibitor Induced Bullous Pemphigoid: A Spanish Multicentric Case Series.Acta dermato-venereologica · 2026Observational
- Article
- Lebrikizumab-induced psoriasis in a patient with atopic dermatitis.JAAD case reports · 2026Article
- Review
- From static pathology to dynamic immunity: immunological plasticity and histopathological remodeling in atopic dermatitis and psoriasis.Frontiers in immunology · 2026Review
- The evaluation of the plasma levels of interleukin 17A, thymic stromal lymphopoietin, interferon gamma, tumor necrosis factor-alpha and interleukins IL-2, IL-6, IL-23, and IL-31 in atopic dermatitis patients with dupilumab treatment.Frontiers in immunology · 2026Article
- Case Report: JAK1 inhibition after dupilumab discontinuation in pediatric atopic dermatitis complicated by pre-existing or emerging vitiligo.Frontiers in pediatrics · 2026Article
- Interleukin-4 and clinical activity in rheumatoid arthritis: a sex-based analysis.Advances in rheumatology (London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDupilumab is the first approved IL-4Rα inhibitor for the treatment of atopic dermatitis at present with good efficacy and safety. However, there have been several reports of psoriasis and psoriasiform manifestations occurring after dupilumab therapy in recent years, showing a new paradoxical cutaneous reaction associated with biologics. SUMMARY: This is a scoping review in order to summarize the demographics and epidemiology, clinical manifestations, diagnosis, potential pathogenesis, and promising management of dupilumab-associated psoriasis and psoriasiform manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.